Zidovudine Kinetics in the Pregnant Baboon
- 1 February 1996
- journal article
- basic science
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 11 (2) , 117-127
- https://doi.org/10.1097/00042560-199602010-00002
Abstract
Summary: The devastating impact of human immunodeficiency virus (HIV) infection during pregnancy has made the pharmacologic evaluation of potentially therapeutic agents of high priority. The results presented here are the maternal pharmacokinetics from a series of experiments to delineate more clearly the complex maternal-fetal pharmacokinetics and the effects of AZT in the chronically instrumented maternal and fetal baboon during both steady state intravenous infusion and oral bolus dosage regimens. Two results of major clinical importance were found. First, during pregnancy, both the clearance and volume of distribution of AZT were increased. Plasma clearance in the pregnant animals was 51 ± 10 ml/min/kg compared with 37 ± 2 ml/min/kg in the nonpregnant animals, and steady state volume of distribution was 3.7 ± 1.21/kg compared with 2.2 ± 0.61/kg. Second, with continuous intravenous infusion plasma drug concentrations were easily maintained in the therapeutic range, whereas with oral administration plasma concentration fell below therapeutic levels within 2 h of the dose being given. Because maternal plasma concentrations are a major determinant of drug concentration achieved in the fetus, an understanding of drug kinetics in pregnancy is of vital importance when making recommendations regarding optimal drug therapy during pregnancy to maximize the beneficial effect—the prevention of HIV infection in children.Keywords
This publication has 33 references indexed in Scilit:
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infectionAntimicrobial Agents and Chemotherapy, 1992
- Summary of the Working Group on Perinatal InterventionAIDS Research and Human Retroviruses, 1992
- Transfer of Zidovudine (AZT) by Human PlacentaThe Journal of Infectious Diseases, 1990
- Azidothymidine (Zidovudine) Transport by the Human PlacentaThe Lancet Healthy Longevity, 1990
- Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV InfectionNew England Journal of Medicine, 1988
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEXThe Lancet, 1986
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985
- Drug disposition and pharmacokinetics in the maternal-placental-fetal unitPharmacology & Therapeutics, 1980